🇺🇸 FDA
Patent

US 12240918

Bispecific antibodies against plasma kallikrein and factor XII

granted A61KA61K39/395A61P

Quick answer

US patent 12240918 (Bispecific antibodies against plasma kallikrein and factor XII) held by Takeda Pharmaceutical Company Limited expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K39/395, A61P, A61P7/02